Welcome to our dedicated page for Resmed SEC filings (Ticker: RSMDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Resmed's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Resmed's regulatory disclosures and financial reporting.
Michael Farrell has filed a notice under Rule 144 indicating a planned sale of 4,991 shares of RMD common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $1,254,795.75. The filing states that 145,966,294 common shares were outstanding at the time of the notice, providing context for the size of this planned sale. The shares to be sold were acquired on 12/08/2025 via an option granted on 11/21/2019 and paid for in cash. The notice also lists prior sales over the past three months, including separate transactions of 8,009, 8,009, and 8,011 common shares, each with disclosed gross proceeds.
Michael Farrell has filed a notice under Rule 144 indicating a planned sale of 4,991 shares of RMD common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $1,254,795.75. The filing states that 145,966,294 common shares were outstanding at the time of the notice, providing context for the size of this planned sale. The shares to be sold were acquired on 12/08/2025 via an option granted on 11/21/2019 and paid for in cash. The notice also lists prior sales over the past three months, including separate transactions of 8,009, 8,009, and 8,011 common shares, each with disclosed gross proceeds.
ResMed Inc. director reports planned stock sale. A reporting person serving as a director of ResMed Inc. (ticker RMD) sold 2,000 shares of ResMed common stock on 12/03/2025 at a price of $251.47 per share. The transaction was coded as a sale and was made under a Rule 10b5-1 trading plan adopted on August 12, 2025, which allows pre-arranged trades according to preset instructions. Following this sale, the insider directly beneficially owns 68,773 shares of ResMed common stock, reflecting the remaining stake reported in this filing.
ResMed Inc. director reports planned stock sale. A reporting person serving as a director of ResMed Inc. (ticker RMD) sold 2,000 shares of ResMed common stock on 12/03/2025 at a price of $251.47 per share. The transaction was coded as a sale and was made under a Rule 10b5-1 trading plan adopted on August 12, 2025, which allows pre-arranged trades according to preset instructions. Following this sale, the insider directly beneficially owns 68,773 shares of ResMed common stock, reflecting the remaining stake reported in this filing.
Peter C Farrell has filed a notice to sell up to 2,000 shares of common stock under Rule 144. The planned sale has an aggregate market value of $502,860, to be executed through Merrill Lynch on or around 12/03/2025 on the NYSE. The filing notes that 44,448,959 shares of this class are outstanding.
The 2,000 shares being sold were acquired through stock option exercises on three dates between 2014 and 2015, all paid in cash. The notice also reports that the same seller disposed of 2,000 common shares in the past three months, on 11/12/2025, generating gross proceeds of $504,020.
Peter C Farrell has filed a notice to sell up to 2,000 shares of common stock under Rule 144. The planned sale has an aggregate market value of $502,860, to be executed through Merrill Lynch on or around 12/03/2025 on the NYSE. The filing notes that 44,448,959 shares of this class are outstanding.
The 2,000 shares being sold were acquired through stock option exercises on three dates between 2014 and 2015, all paid in cash. The notice also reports that the same seller disposed of 2,000 common shares in the past three months, on 11/12/2025, generating gross proceeds of $504,020.
ResMed Inc. reported an insider stock sale by its Global General Counsel. The Form 4 shows that officer Michael J. Rider sold 50 shares of ResMed common stock on 12/01/2025 at a price of $244.16 per share. After this transaction, he beneficially owned 9,791 shares of ResMed common stock directly.
The filing notes that the sale was made under a pre-arranged Rule 10b5-1 trading plan that was adopted on February 28, 2025, which is designed to allow insiders to sell shares according to a set schedule.
ResMed Inc. reported an insider stock sale by its Global General Counsel. The Form 4 shows that officer Michael J. Rider sold 50 shares of ResMed common stock on 12/01/2025 at a price of $244.16 per share. After this transaction, he beneficially owned 9,791 shares of ResMed common stock directly.
The filing notes that the sale was made under a pre-arranged Rule 10b5-1 trading plan that was adopted on February 28, 2025, which is designed to allow insiders to sell shares according to a set schedule.
ResMed Inc.'s Chief Financial Officer reports a routine stock sale. On 12/01/2025, the CFO sold 1,000 shares of ResMed common stock at a price of $244.16 per share in an open market transaction. The filing notes that this sale was conducted under a pre-arranged Rule 10b5-1 trading plan that was adopted on February 19, 2025, which is designed to allow insider transactions under preset instructions.
After this transaction, the CFO continues to beneficially own 87,495 ResMed shares, held directly. The filing does not report any derivative securities transactions, indicating that this update relates only to common stock ownership.
ResMed Inc.'s Chief Financial Officer reports a routine stock sale. On 12/01/2025, the CFO sold 1,000 shares of ResMed common stock at a price of $244.16 per share in an open market transaction. The filing notes that this sale was conducted under a pre-arranged Rule 10b5-1 trading plan that was adopted on February 19, 2025, which is designed to allow insider transactions under preset instructions.
After this transaction, the CFO continues to beneficially own 87,495 ResMed shares, held directly. The filing does not report any derivative securities transactions, indicating that this update relates only to common stock ownership.
An insider of RMD has filed a notice to sell 1,000 shares of common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $244,160. These shares were acquired on 11/11/2022 through restricted stock vesting as compensation from the issuer.
In the past three months, the same seller reported three additional sales: 3,000 shares on 09/02/2025 for gross proceeds of $812,310, 3,000 shares on 10/01/2025 for $823,080, and 3,000 shares on 11/03/2025 for $742,620. The issuer lists 145,966,294 shares of common stock outstanding, providing scale versus these planned and recent insider sales.
An insider of RMD has filed a notice to sell 1,000 shares of common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $244,160. These shares were acquired on 11/11/2022 through restricted stock vesting as compensation from the issuer.
In the past three months, the same seller reported three additional sales: 3,000 shares on 09/02/2025 for gross proceeds of $812,310, 3,000 shares on 10/01/2025 for $823,080, and 3,000 shares on 11/03/2025 for $742,620. The issuer lists 145,966,294 shares of common stock outstanding, providing scale versus these planned and recent insider sales.
ResMed Inc. insider plans sale of common shares under Rule 144. The notice covers a proposed sale of 2,055 common shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $524,025.00. The issuer has 145,966,294 common shares outstanding. The shares derive from restricted stock vesting awards granted as compensation on 11/11/2021 and 11/11/2024.
During the past three months, the same seller, Jan De Witte, sold 487 common shares on 11/11/2025 for gross proceeds of $121,871.75. By signing the notice, the seller represents that he does not know any material adverse information about ResMed’s current or prospective operations that has not been publicly disclosed.
ResMed Inc. insider plans sale of common shares under Rule 144. The notice covers a proposed sale of 2,055 common shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $524,025.00. The issuer has 145,966,294 common shares outstanding. The shares derive from restricted stock vesting awards granted as compensation on 11/11/2021 and 11/11/2024.
During the past three months, the same seller, Jan De Witte, sold 487 common shares on 11/11/2025 for gross proceeds of $121,871.75. By signing the notice, the seller represents that he does not know any material adverse information about ResMed’s current or prospective operations that has not been publicly disclosed.
ResMed Inc. director activity: A company director reported option exercises and related share dispositions in ResMed Inc. common stock. On 11/14/2025, the director exercised 11,442 stock options at an exercise price of $101.64 per share, adding 11,442 shares to their direct holdings. On the same date, 7,314 shares were disposed of at $244.46 per share to cover tax withholding and the cost to exercise options originally granted on 11/14/2018. After these transactions, the director directly owned 70,238 shares of ResMed common stock, and the reported option grant covering 11,442 shares was fully exercised, leaving 0 derivative securities from that grant.
ResMed Inc. director activity: A company director reported option exercises and related share dispositions in ResMed Inc. common stock. On 11/14/2025, the director exercised 11,442 stock options at an exercise price of $101.64 per share, adding 11,442 shares to their direct holdings. On the same date, 7,314 shares were disposed of at $244.46 per share to cover tax withholding and the cost to exercise options originally granted on 11/14/2018. After these transactions, the director directly owned 70,238 shares of ResMed common stock, and the reported option grant covering 11,442 shares was fully exercised, leaving 0 derivative securities from that grant.
ResMed Inc. (RMD) filed a Form 4 reporting a routine insider transaction by director Harjit Gill. On 11/11/2025, 38.209 shares of ResMed common stock were disposed of under transaction code F at a $250.1 price to cover taxes upon vesting of previously granted RSUs. Following this withholding event, Gill beneficially owns 9,867 shares, held directly. The filing notes the RSUs were originally granted on 11/20/2024. This reflects administrative tax withholding rather than an open‑market sale.
ResMed Inc. (RMD) filed a Form 4 reporting a routine insider transaction by director Harjit Gill. On 11/11/2025, 38.209 shares of ResMed common stock were disposed of under transaction code F at a $250.1 price to cover taxes upon vesting of previously granted RSUs. Following this withholding event, Gill beneficially owns 9,867 shares, held directly. The filing notes the RSUs were originally granted on 11/20/2024. This reflects administrative tax withholding rather than an open‑market sale.
ResMed Inc. (RMD) director Mr. Farrell reported two recent stock transactions. On 11/11/2025, he disposed of 162.953 shares of ResMed common stock at $250.10 per share, sent back to the company to cover taxes on the vesting of restricted stock units granted on 11/20/2024. On 11/12/2025, he sold 2,000 shares of ResMed common stock at an average price of $252.05 per share in an open-market transaction. After these actions, he beneficially owns 66,110 shares directly. The sale on 11/12/2025 was made under a Rule 10b5-1 trading plan adopted on August 12, 2025.
ResMed Inc. (RMD) director Mr. Farrell reported two recent stock transactions. On 11/11/2025, he disposed of 162.953 shares of ResMed common stock at $250.10 per share, sent back to the company to cover taxes on the vesting of restricted stock units granted on 11/20/2024. On 11/12/2025, he sold 2,000 shares of ResMed common stock at an average price of $252.05 per share in an open-market transaction. After these actions, he beneficially owns 66,110 shares directly. The sale on 11/12/2025 was made under a Rule 10b5-1 trading plan adopted on August 12, 2025.